PNT
POINT Biopharma Global Inc.
14.06
USD
This page is just a preview of the data found in TrendSpider’s full version
POINT Biopharma Global Inc. stock is up 7.16% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 10 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 29 Nov 16:48 | 19 Jan, 2024 | 12.50 | 52783 | ||
| 30 Nov 19:49 | 19 Jan, 2024 | 15.00 | 25735 | ||
| 01 Dec 16:33 | 19 Jan, 2024 | 12.50 | 52468 | ||
| 01 Dec 18:06 | 19 Jan, 2024 | 12.50 | 52468 | ||
| 01 Dec 18:07 | 19 Jan, 2024 | 12.50 | 52468 | ||
| 01 Dec 18:08 | 19 Jan, 2024 | 12.50 | 52468 | ||
| 04 Dec 16:08 | 19 Jan, 2024 | 12.50 | 52934 | ||
| 08 Dec 14:57 | 19 Jan, 2024 | 12.50 | 55030 | ||
| 08 Dec 19:51 | 19 Jan, 2024 | 12.50 | 55030 | ||
| 08 Dec 20:11 | 19 Jan, 2024 | 15.00 | 29933 |
POINT Biopharma Global Inc. focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioliand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the. treatment of non-metastatic. castration sensitive prostate cancer, which is under study.
